Doctor and assistant talking to female patient

Eliquis® Continues to Differentiate in NVAF

Pfizer, with BMS, continues to generate robust evidence on how Eliquis (apixaban) performs in real-world settings through ACROPOLIS™, which now includes more than 1 million lives analyzed in 11 countries. In 2018, analyses from ARISTOPHANES, the largest known real-world study of oral anticoagulant use in nonvalvular atrial fibrillation (NVAF) patients, were presented at three prominent medical congresses and published in the medical journal, Stroke. Results from ARISTOPHANES complement clinical trial data by providing effectiveness and safety outcomes associated with real-world use of oral anticoagulants in large numbers of NVAF patients who may not have been previously represented in clinical trials.

Go back

Explore Our Innovation